Редактирование: CGAS

Cyclic GMP-AMP synthase (EC 2.7.7.86) (cGAMP synthase) (cGAS) (h-cGAS) (2'3'-cGAMP synthase) (Mab-21 domain-containing protein 1) [C6orf150] [MB21D1]

==Publications==

{{medline-entry
|title=Controlled study of switching from attention-deficit/hyperactivity disorder to a prepubertal and early adolescent bipolar I disorder phenotype during 6-year prospective follow-up: rate, risk, and predictors.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/17064428
|abstract=Rate, risk, and predictors of switching from attention-deficit/hyperactivity disorder (ADHD) to a prepubertal and early adolescent bipolar I disorder phenotype (PEA-BP-I) were examined in a blindly rated, controlled, prospective 6-year follow-up that included assessments at 2-year intervals. Subjects were outpatients obtained by consecutive new case ascertainment. There were 81 subjects who were 9.7  /- 2.0 years. Subjects had DSM-IV ADHD (hyperactive or combined subtypes); a Children's Global Assessment Scale ([[CGAS]]) score of < or =60, consistent with moderate-severe impairment; and no BP or major depressive disorder (MDD) diagnoses. PEA-BP-I was defined as DSM-IV BP I (manic or mixed phase), with cardinal symptoms (elation and/or grandiosity), to avoid diagnosing mania by symptoms that overlapped with those of ADHD, and by a [[CGAS]] score of < or =60. Morbid risk of switching to PEA-BP-I was 28.5%. Significant predictors of switching in a multivariate Cox model were more severe baseline [[CGAS]], paternal recurrent MDD, and less stimulant use. BP I in first-degree relatives, antidepressants, psychosocial measures, and life events were not predictive.
|mesh-terms=* Adolescent
* Aging
* Antidepressive Agents
* Attention Deficit Disorder with Hyperactivity
* Bipolar Disorder
* Central Nervous System Stimulants
* Child
* Female
* Follow-Up Studies
* Humans
* Male
* Nuclear Family
* Outpatients
* Phenotype
* Puberty
* Social Behavior

|full-text-url=https://sci-hub.do/10.1017/S0954579406060512
}}